TQD-3606

评价注射用TQD3606 在中国健康受试者中不同给药时长、不同给药间隔的药物药代动力学（PK）及药代动力学/药效学（PK/PD）特征。 评价注射用TQD3606 在中国健康受试者中不同给药间隔、不同给药时长的耐受性和安全性。

TQD3606 is a fixed-dose combination of meropenem and avibatam. This study is a phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of TQD3606 injection in a single center, randomized, double-blind, placebo-controlled, single and multiple administration in healthy subjects, and to explore the excretion of TQD3606 in urine. To evaluate the tolerability and safety of injectable TQD3606 after single and multiple dosing in healthy subjects.